WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H581828
CAS#: 13329-78-7
Description: Decane-2,4-dione is a biochemical.
Hodoodo Cat#: H581828
Name: Decane-2,4-dione
CAS#: 13329-78-7
Chemical Formula: C10H18O2
Exact Mass: 170.13
Molecular Weight: 170.250
Elemental Analysis: C, 70.55; H, 10.66; O, 18.79
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Decane-2,4-dione; 2,4-decanedione; decane-7,9-dione.
IUPAC/Chemical Name: decane-2,4-dione
InChi Key: WTVNFKVGGUWHQC-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H18O2/c1-3-4-5-6-7-10(12)8-9(2)11/h3-8H2,1-2H3
SMILES Code: C(C(=O)C)C(=O)CCCCCC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 170.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Hu GB, Jiang DW, Li JY, Rao Y, Jiang LY. Crystal structure of (5'S,8'S)-3-(2,5-di-methyl-phen-yl)-8-meth-oxy-3-nitro-1-aza-spiro-[4.5]decane-2, 4-dione. Acta Crystallogr E Crystallogr Commun. 2015 Mar 14;71(Pt 4):o238-9. doi: 10.1107/S2056989015004715. eCollection 2015 Apr 1. PubMed PMID: 26029433; PubMed Central PMCID: PMC4438798.
2: Cervantes-Durán C, Rocha-González HI, Granados-Soto V. Peripheral and spinal 5-HT receptors participate in the pronociceptive and antinociceptive effects of fluoxetine in rats. Neuroscience. 2013 Nov 12;252:396-409. doi: 10.1016/j.neuroscience.2013.08.022. Epub 2013 Aug 27. PubMed PMID: 23994595.
3: Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC, Woods JH. Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther. 2010 Dec;335(3):728-34. doi: 10.1124/jpet.110.172247. Epub 2010 Sep 21. PubMed PMID: 20858706; PubMed Central PMCID: PMC2993545.
4: Nakai K, Nakae A, Oba S, Mashimo T, Ueda K. 5-HT2C receptor agonists attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain. Eur J Pain. 2010 Nov;14(10):999-1006. doi: 10.1016/j.ejpain.2010.04.008. Epub 2010 May 21. PubMed PMID: 20488736.
5: Kashif MK, Khawar Rauf M, Bolte M, Hameed S. 3-(4-Chloro-phenyl-sulfon-yl)-8-methyl-1,3-diaza-spiro-[4.5]decane-2,4-dione. Acta Crystallogr Sect E Struct Rep Online. 2009 Jul 18;65(Pt 8):o1893. doi: 10.1107/S1600536809027482. PubMed PMID: 21583583; PubMed Central PMCID: PMC2977302.
6: Kashif MK, Khawar Rauf M, Bolte M, Hameed S. 3-(4-Bromo-phenyl-sulfon-yl)-8-methyl-1,3-diaza-spiro-[4.5]decane-2,4-dione. Acta Crystallogr Sect E Struct Rep Online. 2009 Jul 18;65(Pt 8):o1892. doi: 10.1107/S1600536809027305. PubMed PMID: 21583582; PubMed Central PMCID: PMC2977264.
7: Cordeaux Y, Pasupathy D, Bacon J, Charnock-Jones DS, Smith GC. Characterization of serotonin receptors in pregnant human myometrium. J Pharmacol Exp Ther. 2009 Mar;328(3):682-91. doi: 10.1124/jpet.108.143040. Epub 2008 Dec 15. PubMed PMID: 19075042.
8: Qiu J, Xue C, Bosch MA, Murphy JG, Fan W, Rønnekleiv OK, Kelly MJ. Serotonin 5-hydroxytryptamine2C receptor signaling in hypothalamic proopiomelanocortin neurons: role in energy homeostasis in females. Mol Pharmacol. 2007 Oct;72(4):885-96. Epub 2007 Jul 10. PubMed PMID: 17622577.
9: Liu FY, Xing GG, Qu XX, Xu IS, Han JS, Wan Y. Roles of 5-hydroxytryptamine (5-HT) receptor subtypes in the inhibitory effects of 5-HT on C-fiber responses of spinal wide dynamic range neurons in rats. J Pharmacol Exp Ther. 2007 Jun;321(3):1046-53. Epub 2007 Feb 28. PubMed PMID: 17329553.
10: Kitazawa T, Ukai H, Komori S, Taneike T. Pharmacological characterization of 5-hydroxytryptamine-induced contraction in the chicken gastrointestinal tract. Auton Autacoid Pharmacol. 2006 Apr;26(2):157-68. PubMed PMID: 16553644.
11: Kelly CR, Sharif NA. Pharmacological evidence for a functional serotonin-2B receptor in a human uterine smooth muscle cell line. J Pharmacol Exp Ther. 2006 Jun;317(3):1254-61. Epub 2006 Mar 3. PubMed PMID: 16517693.
12: Ramos M, Goñi-Allo B, Aguirre N. Administration of SCH 23390 into the medial prefrontal cortex blocks the expression of MDMA-induced behavioral sensitization in rats: an effect mediated by 5-HT2C receptor stimulation and not by D1 receptor blockade. Neuropsychopharmacology. 2005 Dec;30(12):2180-91. PubMed PMID: 15841107.
13: Bishop C, Tessmer JL, Ullrich T, Rice KC, Walker PD. Serotonin 5-HT2A receptors underlie increased motor behaviors induced in dopamine-depleted rats by intrastriatal 5-HT2A/2C agonism. J Pharmacol Exp Ther. 2004 Aug;310(2):687-94. Epub 2004 Mar 25. PubMed PMID: 15044557.
14: Filip M, Cunningham KA. Hyperlocomotive and discriminative stimulus effects of cocaine are under the control of serotonin(2C) (5-HT(2C)) receptors in rat prefrontal cortex. J Pharmacol Exp Ther. 2003 Aug;306(2):734-43. Epub 2003 Apr 29. PubMed PMID: 12721337.
15: McMahon LR, Filip M, Cunningham KA. Differential regulation of the mesoaccumbens circuit by serotonin 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors. J Neurosci. 2001 Oct 1;21(19):7781-7. PubMed PMID: 11567068.
16: Steardo L, Monteleone P, Trabace L, Cannizzaro C, Maj M, Cuomo V. Serotonergic modulation of rat pineal gland activity: in vivo evidence for a 5-Hydroxytryptamine(2C) receptor involvement. J Pharmacol Exp Ther. 2000 Oct;295(1):266-73. PubMed PMID: 10991989.
17: Kossakowski J, Zawadowski T, Turło J, Kleps J. Synthesis of N-(4-aryl-1-piperazinylbutyl)-substituted 7,8-benzo-1,3-diazaspiro[4,5]decane-2,4-dione derivatives with potential anxiolytic activity. Farmaco. 1998 Feb;53(2):169-71. PubMed PMID: 9604324.
18: Bonhaus DW, Weinhardt KK, Taylor M, DeSouza A, McNeeley PM, Szczepanski K, Fontana DJ, Trinh J, Rocha CL, Dawson MW, Flippin LA, Eglen RM. RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology. 1997 Apr-May;36(4-5):621-9. PubMed PMID: 9225287.
19: Tsukamoto S, Ichihara M, Wanibuchi F, Usuda S, Hidaka K, Harada M, Tamura T. Synthesis and structure-activity studies of a series of spirooxazolidine-2,4-diones: 4-oxa analogues of the muscarinic agonist 2-ethyl-8-methyl-2,8-diazaspiro[4.5]decane-1,3-dione. J Med Chem. 1993 Aug 6;36(16):2292-9. PubMed PMID: 8360873.
